TerminatedPhase 3

HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin

Stopped: Difficulty in patient recruitment

Spain108 participantsStarted 2013-03-10

Plain-language summary

The primary objective of this study is to evaluate the safety and efficacy of a Response Guided Therapy of boceprevir 800 mg dosed three times a day (TID) orally (PO) in combination with Peginterferon (either alpha 2b or alpha 2a) and Ribavirin in HIV/HCV genotype 1 infected patients that failed to previous HCV therapy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. No cirrhosis. Biopsies and/or Fibroscan must be within 18 months of screening visit.
✓. Cirrhosis. No specific length of time would be requested.

What they're measuring

Achievement of Sustained Virological Response (SVR) at 24 Weeks Post-Treatment

Timeframe: Week 24

Trial details

NCT IDNCT01718301

SponsorAnna Cruceta

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2015-03-20

Results submitted2015-09-01

View on ClinicalTrials.gov More Hepatitis C trials